NCT03543670View on ClinicalTrials.gov

Evaluation of Oncoxin-Viusid® in Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

September 16, 2017

Primary Completion Date

April 12, 2018

Study Completion Date

December 30, 2018

Conditions
Prostate Cancer
Interventions
DIETARY_SUPPLEMENT

Oncoxin-Viusid

Support treatment with Oncoxin-Viusid (75mL/day) during chemotherapy/Radiotherapy until two weeks after (a total of 8 months).

Trial Locations (1)

10400

General Calixto García University Hospital, La Habana

All Listed Sponsors
lead

Catalysis SL

INDUSTRY

NCT03543670 - Evaluation of Oncoxin-Viusid® in Prostate Cancer | Biotech Hunter | Biotech Hunter